AlphAIAlphAI — Financial news for AI agents
investing.com$RMD

Mizuho raises ResMed stock price target to $270 on resupply strength

Mizuho raised its price target for ResMed (NYSE:RMD) to $270 from $240, citing strong resupply segment performance. The company beat earnings estimates, reporting $1.4B revenue and $2.91 EPS, but warned of near-term margin pressures. ResMed maintains 5-7% revenue growth guidance.

Original reporting
investing.com
Published Oct 30, 2026, 10:06 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 10:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$RMD
Bullish
high confidence
Mentioned
$RMD
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RMDBullishMed
01

Why it matters

The earnings beat and target raise provide a fresh catalyst for the stock, likely prompting buying interest.

02

Market read

Earnings beat and analyst upgrade create a short‑term bullish bias for RMD.

03

What to watch

Potential margin pressure noted by management could temper enthusiasm.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

ResMed reported fiscal Q1 earnings that exceeded forecasts, with revenue of $1.4 B and adjusted EPS of $2.91.

Company-level read

Ticker impact

$RMDBullishHigh confidence
Context

Mizuho raised its price target on ResMed to $270 after the company beat earnings expectations and posted a strong Resupply segment.

Expected impact

likely upward pressure as investors price in the higher target and beat.

Evidence & confidence

Analyst target raise combined with earnings beat provides a fresh catalyst.

Market effects

Sector

Strong results may lift the broader medical device sector.

Regional

Positive for U.S. healthcare stocks.

Global

Limited to investors tracking US med‑tech equities.

Counterpoint

What could challenge this read

Some may argue the target raise is modest given the beat, limiting upside.

Key entities

  • company
    ResMed Inc.

    Medical device maker specializing in sleep apnea equipment.

  • analyst
    Mizuho

    Investment bank that raised the price target.

Read at source← All news

StoryResMed posts Q1 FY27 beat with $1.4 B revenue, $2.91 EPS and $1 B returned to shareholders

Also covered by

4 outlets

Related articles

$RMDMedAI 8/10

What Sent ResMed Stock Lower?

ResMed (RMD) shares dropped 9.1% on October 30, 2026, following its fiscal Q1 2027 earnings release. The company beat earnings and revenue estimates, with EPS of $2.91 and revenue of $1.41B. Despite 14% higher EPS YoY, revenue growth slowed to 5.9%. Peers also fell, with Stryker (SYK) down 6.4% after missing estimates. The broader market declined due to AI sector selloff. ResMed's stock is down 8.4% over the past year.

finance.yahoo.com
$RMDMed

ResMed (RMD) Q1 2027 Earnings Call Transcript

ResMed (RMD) reported Q1 2027 earnings, highlighting innovation in sleep health products, including new bilevel devices and fabric masks. The company saw a 6% increase in therapy adherence with fabric masks and 4.3% with AI-driven Smart Comfort. ResMed also improved gross margins and expanded U.S. manufacturing. The myAir app, with 13M+ downloads, enhances patient engagement and compliance.

finance.yahoo.com
$RMDMedAI 8/10

What ResMed (RMD) Said on Its Q1 Earnings Call

ResMed (RMD) reported Q1 residential care software revenue declined 7% but increased 5% on a constant-currency basis. The company launched new devices and digital tools, with management highlighting growth in patient engagement. Non-GAAP gross margin rose to 62.5%. ResMed maintained its fiscal 2027 guidance, expecting 5-7% core revenue growth and EPS of $12-$12.25. The company is expanding U.S. manufacturing and discontinuing Astral ventilators.

finance.yahoo.com
$RMDHighAI 8/10

ResMed 3Q 2026: Revenue $1.41B, EPS $2.92— 10-Q Summary

ResMed reported 3Q 2026 revenue of $1.41B, up 5.9% YoY, with net income rising 20% to $418.41M and EPS increasing 23.2% to $2.92. Sleep and Breathing Health revenue grew 8%, while Residential software revenue declined 7% post-MatrixCare sale. The company completed the MatrixCare divestiture and expects input-cost inflation to persist through fiscal 2027.

tradingview.com